Barbexaclone

Summary

Barbexaclone (Maliasin) is a salt compound of phenobarbital and levopropylhexedrine.[2] It was introduced in 1983. It has been reported to be as effective as phenobarbital but better tolerated; however, as of 2004, these "promising results"[3] had not yet been confirmed nor denied in controlled trials.

Barbexaclone
Combination of
PhenobarbitalBarbiturate
LevopropylhexedrineSympathomimetic
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Legal status
Legal status
Identifiers
CAS Number
  • 4388-82-3 checkY
PubChem CID
  • 71196
DrugBank
  • DB09001 ☒N
ChemSpider
  • 64332 checkY
UNII
  • 291GX1YB65
CompTox Dashboard (EPA)
  • DTXSID90195974 Edit this at Wikidata
ECHA InfoCard100.022.278 Edit this at Wikidata
 ☒NcheckY (what is this?)  (verify)

Potency edit

100 mg of barbexaclone is equivalent to 60 mg of phenobarbital.[2]

References edit

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ a b Shorvon S, Perucca E, Engel Jr J (23 September 2015). The Treatment of Epilepsy. Wiley. pp. 1706–1707. ISBN 978-1-118-93699-3.
  3. ^ Salles Barbosa MF (September 1978). "[Barbexaclone in the treatment of cerebral dysrhythmia]". Arquivos de Neuro-Psiquiatria. 36 (3): 245–249. doi:10.1590/s0004-282x1978000300009. PMID 28716.

Further reading edit

  • Shorvon SR, Fish DR, Perucca E, Dodson WE, eds. (2004). The Treatment of Epilepsy (2nd ed.). Published by Blackwell. p. 472. ISBN 0-632-06046-8.